Procarbazine is an antineoplastic agent indicated for the treatment of stage III and stage IV Hodgkin's disease in combination with other chemotherapeutic agents. An anticancer medication used to treat a type of blood cancer.
- Mechanism
- Curator reviewed
The precise mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit transmethylation of methyl groups of methionine into t-RNA. The absence of functional t-RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA. Hydrogen peroxide, formed during the auto-oxidation of the drug, may attack protein sulfhydryl groups contained in residual protein which is tightly bound to DNA.
- Primary indication
- For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.Curator reviewed · 5 structured indications
- Formula / weight
- C12H19N3O · 221.2988 g/mol (avg)
- First approval
- Canada, 2017 · United States, 1985
- Code names
- RO-4-6467
- Brand names
Resolves to
CPTBDICYNRMXFX-UHFFFAOYSA-NSMILESCNNCC1=CC=C(C=C1)C(=O)NC(C)CWhat you can answer from here — as of September 23, 2026
Which other approved drugs treat the same conditions as Procarbazine, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account